[ 英語タイトル ] Middle East and Africa (MEA) Kidney Cancer Therapeutics & Diagnostics Market - Growth, Trends, and Forecast (2020–2025)

Product Code : MDHC0088861

Survey : Mordor Intelligence

Publish On : November, 2020

Number of Pages : 90

Category : Healthcare and Pharmaceuticals

Study Area : Middle East Africa

Report format : PDF

Sales price option (consumption tax not included)

[Report Description]

The Middle East and Africa Kidney Cancer Therapeutics & Diagnostics market studied was projected to grow with a CAGR of 5.2% over the forecast period. The market will show rapid growth due to the rising number of kidney cancer cases in the region and the increasing R&D expenditure of pharmaceutical companies. Excessive smoking, an increase in obesity due to longevity, and increased intake of alcohol are some of the causes of kidney cancer in the region. According to the Global Cancer Observatory, in Saudi Arabia there are 830 new kidney cancer cases were registered in 2018, furthermore, 249 people were died due to the diseases. Though the prevalence of kidney cancer cases in the region is less compared to the other region of the world, the incidence is still increasing from past years due to the change in lifestyle. Furthermore, the high cost associated with the treatment is restraining the market.

Key Market Trends

Clear cell RCC is Expected to be the Largest Growing Segment in the Kidney Cancer Therapeutics & Diagnostics Market

Clear cell renal cell carcinoma, or ccRCC, is a type of kidney cancer. and is named after how the tumor looks under the microscope. There are various treatments for people with ccRCC include surgery, immunotherapy, and targeted therapy.

Targeted therapy targets the changes in cancer cells that help them grow, divide, and spread. Some targeted therapies that are used to treat clear cell renal carcinoma include cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib. According to the Global Burden of Diseases report 2017, the number of incident kidney cancer cases of the Middle East and Africa are recorded to be 15,082. According to Globocan, in 2018, 1,077 new kidney cancer cases were diagnosed, and 582 deaths were reported due to kidney cancer in South Africa. The growing incidence of the early diagnosis and treatment of these cancers is boosting the segment growth.

Competitive Landscape

The Middle East and Africa Kidney Cancer Therapeutics & Diagnostics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Abbott Laboratories, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Amgen Inc., Merck & Co. Inc.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support